Loading...

BML

MUN:BMZ
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BMZ
MUN
¥133B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

BML, Inc. provides laboratory testing and related services in Japan. The last earnings update was 65 days ago. More info.


Add to Portfolio Compare Print
BMZ Share Price and Events
7 Day Returns
-0%
MUN:BMZ
-4.7%
DE Healthcare
1.8%
DE Market
1 Year Returns
18%
MUN:BMZ
-21.4%
DE Healthcare
-6%
DE Market
BMZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BML (BMZ) -0% -6.4% 3.7% 18% 29.6% 76.9%
DE Healthcare -4.7% -0.5% 12.1% -21.4% -18.6% 37.3%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • BMZ outperformed the Healthcare industry which returned -21.4% over the past year.
  • BMZ outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
BMZ
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for BML's competitors could be found in our database.

BMZ Value

 Is BML undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BML to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BML.

MUN:BMZ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for MUN:BMZ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.71
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.711 (1 + (1- 30.86%) (0%))
0.807
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.807 * 5.96%)
5.03%

Discounted Cash Flow Calculation for MUN:BMZ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BML is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

MUN:BMZ DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 5.03%)
2019 8,490.00 Analyst x1 8,083.03
2020 8,107.50 Analyst x2 7,348.86
2021 8,796.00 Analyst x2 7,590.74
2022 9,135.00 Analyst x2 7,505.40
2023 9,557.50 Analyst x2 7,476.12
2024 10,218.00 Analyst x1 7,609.64
2025 10,580.72 Est @ 3.55% 7,502.05
2026 10,850.87 Est @ 2.55% 7,324.80
2027 11,052.22 Est @ 1.86% 7,103.09
2028 11,203.35 Est @ 1.37% 6,855.07
Present value of next 10 years cash flows ¥74,398.78
MUN:BMZ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥11,203.35 × (1 + 0.23%) ÷ (5.03% – 0.23%)
¥233,599.50
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥233,599.50 ÷ (1 + 5.03%)10
¥142,934.04
MUN:BMZ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥74,398.78 + ¥142,934.04
¥217,332.82
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥217,332.82 / 42.60
¥5102.08
MUN:BMZ Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in MUN:BMZ represents 0.0077x of TSE:4694
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.0077x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 5,102.08 x 0.0077
€39.31
Value per share (EUR) From above. €39.31
Current discount Discount to share price of €24.12
= -1 x (€24.12 - €39.31) / €39.31
38.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BML is available for.
Intrinsic value
39%
Share price is €24.12 vs Future cash flow value of €39.31
Current Discount Checks
For BML to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BML's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BML's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BML's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BML's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
MUN:BMZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥152.57
TSE:4694 Share Price ** TSE (2019-04-18) in JPY ¥3130
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 34.55x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BML.

MUN:BMZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4694 Share Price ÷ EPS (both in JPY)

= 3130 ÷ 152.57

20.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BML is good value based on earnings compared to the DE Healthcare industry average.
  • BML is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does BML's expected growth come at a high price?
Raw Data
MUN:BMZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 20.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
6.3%per year
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

MUN:BMZ PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 20.51x ÷ 6.3%

3.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BML is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on BML's assets?
Raw Data
MUN:BMZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥1,794.21
TSE:4694 Share Price * TSE (2019-04-18) in JPY ¥3130
Germany Healthcare Industry PB Ratio Median Figure of 12 Publicly-Listed Healthcare Companies 1.5x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
MUN:BMZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4694 Share Price ÷ Book Value per Share (both in JPY)

= 3130 ÷ 1,794.21

1.74x

* Primary Listing of BML.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BML is overvalued based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess BML's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. BML has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BMZ Future Performance

 How is BML expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BML expected to grow at an attractive rate?
  • BML's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BML's earnings growth is positive but not above the Germany market average.
  • BML's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
MUN:BMZ Future Growth Rates Data Sources
Data Point Source Value (per year)
MUN:BMZ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 6.3%
MUN:BMZ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 2.9%
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 3.1%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
MUN:BMZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
MUN:BMZ Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31
2023-03-31 131,600 14,020 7,920 1
2022-03-31 127,350 13,367 8,415 2
2021-03-31 122,250 13,121 7,515 4
2020-03-31 119,775 12,522 7,138 4
2019-03-31 116,600 12,006 6,588 4
MUN:BMZ Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 115,923 6,497
2018-09-30 114,387 11,713 5,990
2018-06-30 114,375 6,196
2018-03-31 113,502 12,079 5,988
2017-12-31 113,127 6,073
2017-09-30 112,620 12,172 6,105
2017-06-30 111,803 5,869
2017-03-31 111,243 11,307 5,948
2016-12-31 111,245 6,156
2016-09-30 110,936 12,050 6,249
2016-06-30 109,990 5,977
2016-03-31 109,024 11,978 5,424

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BML's earnings are expected to grow by 6.3% yearly, however this is not considered high growth (20% yearly).
  • BML's revenue is expected to grow by 2.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
MUN:BMZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from BML Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MUN:BMZ Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31
2023-03-31 185.93 185.93 185.93 1.00
2022-03-31 197.54 218.30 176.77 2.00
2021-03-31 176.42 199.50 166.99 4.00
2020-03-31 167.59 185.50 159.23 4.00
2019-03-31 154.65 159.60 148.20 4.00
MUN:BMZ Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 152.57
2018-09-30 140.71
2018-06-30 145.62
2018-03-31 140.81
2017-12-31 142.88
2017-09-30 143.69
2017-06-30 138.15
2017-03-31 140.01
2016-12-31 144.91
2016-09-30 147.10
2016-06-30 140.70
2016-03-31 127.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • BML is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess BML's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BML has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BMZ Past Performance

  How has BML performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BML's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BML's year on year earnings growth rate has been positive over the past 5 years.
  • BML's 1-year earnings growth is less than its 5-year average (7% vs 8.3%)
  • BML's earnings growth has not exceeded the DE Healthcare industry average in the past year (7% vs 12.5%).
Earnings and Revenue History
BML's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BML Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MUN:BMZ Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 115,923.00 6,497.00 31,282.00 326.00
2018-09-30 114,387.00 5,990.00 31,168.00 326.00
2018-06-30 114,375.00 6,196.00 31,020.00 326.00
2018-03-31 113,502.00 5,988.00 30,800.00 326.00
2017-12-31 113,127.00 6,073.00 30,669.00 302.00
2017-09-30 112,620.00 6,105.00 30,374.00 302.00
2017-06-30 111,803.00 5,869.00 30,346.00 302.00
2017-03-31 111,243.00 5,948.00 30,168.00 302.00
2016-12-31 111,245.00 6,156.00 30,203.00 265.00
2016-09-30 110,936.00 6,249.00 30,181.00 265.00
2016-06-30 109,990.00 5,977.00 30,105.00 265.00
2016-03-31 109,024.00 5,424.00 30,161.00 265.00
2015-12-31 107,444.00 4,469.00 30,020.00 285.00
2015-09-30 106,067.00 4,178.00 29,932.00 285.00
2015-06-30 105,214.00 3,748.00 29,927.00 285.00
2015-03-31 104,404.00 3,874.00 29,692.00 285.00
2014-12-31 103,218.00 4,357.00 29,393.00 302.00
2014-09-30 101,952.00 4,484.00 28,989.00 302.00
2014-06-30 100,522.00 4,932.00 28,432.00 302.00
2014-03-31 99,047.00 4,990.00 27,951.00 302.00
2013-12-31 97,776.00 4,860.00 27,672.00 266.00
2013-09-30 96,811.00 4,667.00 27,662.00 266.00
2013-06-30 95,847.00 4,276.00 27,626.00 266.00
2013-03-31 94,608.00 3,708.00 27,751.00 266.00
2012-12-31 94,222.00 3,324.00 28,105.00 322.00
2012-09-30 93,359.00 2,694.00 27,867.00 322.00
2012-06-30 92,800.00 2,250.00 27,865.00 322.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BML has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • BML used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • BML has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess BML's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BML has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BMZ Health

 How is BML's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BML's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BML is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BML's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BML's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • BML has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BML Company Filings, last reported 3 months ago.

MUN:BMZ Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 80,294.00 0.00 49,693.00
2018-09-30 79,272.00 0.00 49,681.00
2018-06-30 77,541.00 0.00 46,344.00
2018-03-31 76,220.00 3,217.00 46,327.00
2017-12-31 74,773.00 0.00 44,272.00
2017-09-30 73,940.00 0.00 44,683.00
2017-06-30 71,816.00 0.00 41,327.00
2017-03-31 70,645.00 3,310.00 41,281.00
2016-12-31 69,243.00 0.00 40,416.00
2016-09-30 68,238.00 0.00 39,809.00
2016-06-30 66,526.00 0.00 36,877.00
2016-03-31 65,205.00 3,203.00 37,037.00
2015-12-31 65,078.00 0.00 34,675.00
2015-09-30 64,083.00 0.00 34,064.00
2015-06-30 62,700.00 0.00 30,893.00
2015-03-31 61,967.00 3,411.00 31,024.00
2014-12-31 60,986.00 930.00 28,965.00
2014-09-30 60,135.00 940.00 28,267.00
2014-06-30 59,134.00 930.00 25,339.00
2014-03-31 57,655.00 4,578.00 27,597.00
2013-12-31 56,679.00 930.00 25,498.00
2013-09-30 55,662.00 930.00 25,551.00
2013-06-30 54,199.00 998.00 22,432.00
2013-03-31 52,942.00 4,420.00 22,336.00
2012-12-31 52,213.00 1,033.00 20,429.00
2012-09-30 51,350.00 1,036.00 20,183.00
2012-06-30 50,320.00 4,617.00 17,649.00
  • BML has no debt.
  • BML has no debt compared to 5 years ago when it was 1.7%.
  • BML has no debt, it does not need to be covered by operating cash flow.
  • BML has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess BML's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BML has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BMZ Dividends

 What is BML's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.21%
Current annual income from BML dividends. Estimated to be 1.44% next year.
If you bought €2,000 of BML shares you are expected to receive €24 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • BML's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.43%).
  • BML's dividend is below the markets top 25% of dividend payers in Germany (3.72%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
MUN:BMZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.6%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

MUN:BMZ Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31 47.00 1.00
2022-03-31 50.00 2.00
2021-03-31 44.67 3.00
2020-03-31 41.67 3.00
2019-03-31 38.67 3.00
MUN:BMZ Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-02-14 38.000 1.166
2019-02-08 38.000 1.119
2018-11-14 38.000 1.317
2018-11-09 38.000 1.353
2018-08-14 38.000 1.181
2018-08-09 38.000 1.222
2018-06-28 38.000 1.366
2018-05-11 38.000 1.356
2018-02-14 35.000 1.300
2018-02-09 35.000 1.388
2017-11-14 35.000 1.247
2017-11-08 35.000 1.321
2017-06-29 35.000 1.481
2017-05-10 35.000 1.551
2017-02-14 35.000 1.422
2017-02-10 35.000 1.394
2016-11-11 35.000 1.286
2016-11-08 35.000 1.324
2016-06-29 35.000 1.364
2016-05-10 35.000 1.428
2015-06-26 30.000 1.571
2015-05-11 30.000 1.606
2015-02-09 30.000 1.731
2014-11-11 30.000 1.852
2014-08-14 30.000 1.807
2014-06-27 25.000 1.257
2014-05-12 25.000 1.278
2014-02-14 30.000 1.633
2014-02-06 30.000 1.788
2013-11-14 20.000 1.158
2013-06-27 20.000 1.378
2013-05-13 20.000 1.605
2013-02-14 20.000 1.613
2013-02-07 20.000 1.783
2012-11-14 20.000 1.869
2012-11-12 20.000 1.929
2012-08-09 20.000 1.971
2012-06-28 20.000 1.922
2012-05-14 20.000 2.071
2012-02-14 20.000 1.978
2012-02-09 20.000 2.005
2011-11-14 20.000 2.164
2011-11-10 20.000 2.106
2011-08-09 20.000 2.009
2011-06-29 20.000 1.932
2011-05-12 20.000 1.955
2011-02-10 20.000 1.743
2010-11-11 20.000 1.799
2010-06-25 20.000 1.952
2010-05-13 20.000 1.906
2010-02-10 15.000 1.298
2009-11-12 15.000 1.160
2009-06-26 15.000 1.287
2009-05-13 15.000 1.522
2009-04-21 15.000 1.720

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of BML's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4.2x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BML's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BML afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BML has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BMZ Management

 What is the CEO of BML's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kensuke Kondo
AGE 52
TENURE AS CEO 5.3 years
CEO Bio

Mr. Kensuke Kondo has been President of BML Inc. since January 2014 and served as its Executive Officer and Assistant General Manager of Administrative Division since October 2011 and has been its Representative Director since June 1994. Mr. Kondo serves as Operating Officer at BML Inc. Mr. Kondo has been Chairman and Representative Director at OPL Corporation since June 2014. He has been the Chairman and Representative Director at Kyodo Igaku Laboratories, Inc since June 2014. He has been Chairman and Representative Director at QOL Central Laboratories Co., Ltd since June 2014. He has been Chairman and Representative Director at Q-syu Open Laboratories, Inc. since June 2014. He served as Assistant General Manager of Administration Division at BML Kikaku, Inc since April 2013. He served as General Manager of Advanced Technology Development Division and Assistant General Manager of Sales Management Division at BML Kikaku, Inc since October 2011. He has been President and Representative Director at BML Kikaku, Inc since August 1998. He has been President and Representative Director at Estate Kogyo, Ltd since August 1995.

CEO Compensation
  • Insufficient data for Kensuke to compare compensation growth.
  • Insufficient data for Kensuke to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BML management team in years:

3.5
Average Tenure
58
Average Age
  • The tenure for the BML management team is about average.
Management Team

Kensuke Kondo

TITLE
President
AGE
52
TENURE
5.3 yrs

Masaaki Hirose

TITLE
Senior Executive Officer & Director
AGE
62
TENURE
2.3 yrs

Nobuki Arai

TITLE
Sr. Managing Executive Officer
AGE
58
TENURE
1.8 yrs

Masato Chikira

TITLE
Managing Executive Officer
AGE
63
TENURE
4.8 yrs

Masao Nakagawa

TITLE
Managing Exec. Officer
AGE
63
TENURE
6.8 yrs

Satoshi Enomoto

TITLE
Operating Officer & Director
AGE
57
TENURE
1.3 yrs

Yasushi Narabe

TITLE
Operating Officer & Director

Norihisa Takebe

TITLE
Operating Officer & Director
AGE
56
Board of Directors Tenure

Average tenure and age of the BML board of directors in years:

4.8
Average Tenure
60
Average Age
  • The tenure for the BML board of directors is about average.
Board of Directors

Kensuke Kondo

TITLE
President
AGE
52
TENURE
24.8 yrs

Masaaki Hirose

TITLE
Senior Executive Officer & Director
AGE
62
TENURE
1.3 yrs

Nobuki Arai

TITLE
Sr. Managing Executive Officer
AGE
58
TENURE
9.8 yrs

Masato Chikira

TITLE
Managing Executive Officer
AGE
63
TENURE
6.8 yrs

Masao Nakagawa

TITLE
Managing Exec. Officer
AGE
63
TENURE
4.8 yrs

Satoshi Enomoto

TITLE
Operating Officer & Director
AGE
57

Yasushi Narabe

TITLE
Operating Officer & Director
TENURE
1.3 yrs

Norihisa Takebe

TITLE
Operating Officer & Director
AGE
56

Kunikatsu Yamamoto

TITLE
Outside Director
AGE
76

Kouichi Sekiya

TITLE
Outside Director
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess BML's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BML has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BMZ News

Simply Wall St News

BMZ Company Info

Description

BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis; microbiological tests for medical and pharmaceutical societies and organizations; and laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies. It also develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, as well as subsequent test procedures; and provides electronic medical charts for networking medical information, as well as preventive medicine services. In addition, the company offers food sanitation control and food processing services comprising contract services for microorganism testing of raw materials, and prepared and processed foods; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and waste water tests; work sanitation management support services, such as measurement of ethylene oxide gas, formaldehyde, organic solvents, and dust; environmental monitoring services, including measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal disease; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. BML, Inc. was founded in 1955 and is headquartered in Tokyo, Japan.

Details
Name: BML, Inc.
BMZ
Exchange: MUN
Founded: 1955
¥1,059,193,489
42,596,902
Website: http://www.bml.co.jp
Address: BML, Inc.
5-21-3 Sendagaya,
Shibuya-ku,
Tokyo,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4694 Common Stock The Tokyo Stock Exchange JP JPY 30. Nov 1999
MUN BMZ Common Stock Boerse Muenchen DE EUR 30. Nov 1999
Number of employees
Current staff
Staff numbers
3,902
BML employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 20:46
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/19
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.